CMS Cancelled Coverage for 760,000 People and Froze New Brokers for 2027 Over Unauthorized Enrollments
CMS frames this as fraud recovery. Its release says much less about the 760,000 people whose marketplace coverage ends.
Quick
The daily shorts. One story, one insight.
Medicare’s Preliminary Lab Rates Cut Genomic Sequencing 23% and Proprietary Tests Just 2.4%
The average cut is 16%. The tests carrying the newest science take the deepest cuts, and proprietary ones barely move.
Boehringer’s $1 Billion Cancer Deal Will Pay to Put Envisagenics’ ALS Drug Into the Clinic
Boehringer is buying options on cancer targets. Envisagenics plans to spend the money taking an ALS drug into the clinic.
Beacon Succeeded in XLRP Where Biogen and J&J Failed, on an Endpoint Neither of Them Used
QuickCI read/Ophthalmology/Cell & Gene Tx Beacon Succeeded in XLRP Where Biogen and J&J Failed, on an Endpoint Neither of Them Used Athithi Verma· 22 September 2026· 2 min read· Synopulse Beacon Therapeutics said on 21 September 2026 that laru-zova met the FDA-endorsed primary endpoint of VISTA, a 12-month randomised trial in 85 males aged 12 … Read more
Brazil Approved AstraZeneca’s Camizestrant 17 Days After the FDA, Whose Own Advisers Had Voted Against It
Every major regulator has now said yes to a strategy the FDA’s advisers doubted. The constraint is a blood test.
Novartis’s $900 Million BoomRay Licence Names No Target, No Isotope and No Upfront
Without an upfront, a target or an isotope, BoomRay’s $900 million headline is a ceiling rather than a valuation.
Caplyta Doubled the Mania Response Rate, and Only Dry Mouth and Nausea Cleared J&J’s Side Effect Bar
The efficacy is the headline. The competitive case sits in the side effect line, and it points at AbbVie’s Vraylar.
UnitedHealthcare Is Enlisting Doctors Against the Paperwork Behind 43% of Projected Medicaid Losses
CMS expects much of the coverage loss to come from process, not from failing the test. The insurer asked doctors to help.
China Ordered Rare Disease Clinics in Every Province by December and Left Payment Out
Every instruction raises the number of diagnosed patients. None addresses what they can be prescribed, or who pays.
Merck Moved Every Japanese Keytruda Indication to a One-Minute Injection on a Single Lung Cancer Trial
One exposure trial in lung cancer carried every Japanese indication. The contest is now minutes and millilitres.